Tenaya Slashes a Third of Workforce To Fund Development of Cardio Gene Therapies

The layoffs will take place throughout 2025 and will mostly affect Tenaya’s research and manufacturing operations. The company is continuing to test its hypertrophic cardiomyopathy gene therapy.